VLC
PFE icon

Van Leeuwen & Company’s Pfizer PFE Stock Holding History

Van Leeuwen & Company’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-98,346
Closed -$5.04M – 79
2022
Q4 		$5.04M Sell
98,346
-933
-0.9% -$44.7K 3.48% 12
2022
Q3 		$4.34M Buy
99,279
+49,375
+99% +$2.4M 3.46% 11
2022
Q2 		$2.62M Buy
+49,904
New +$2.54M 2.19% 16
2019
Q3 		– Sell
-45,815
Closed -$1.88M – 80
2019
Q2 		$1.88M Buy
45,815
+84
+0.2% +$3.34K 1.69% 25
2019
Q1 		$1.84M Buy
45,731
+36,426
+391% +$1.46M 1.73% 23
2018
Q4 		$385K Buy
9,305
+343
+4% +$14.2K 0.38% 56
2018
Q3 		$375K Buy
+8,962
New +$345K 0.35% 62

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Van Leeuwen & Company's PFE Position: Q1 2023 in Review

Van Leeuwen & Company sold out of Pfizer (PFE) in Q1 2023, closing a stake of 98,346 shares — an estimated $5.04M sold.

Van Leeuwen & Company first reported a position in PFE in Q3 2018 and held it in 7 quarters. The position peaked at $5.04M in Q4 2022. 3,103 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

  • Van Leeuwen & Company reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
  • Van Leeuwen & Company sold 98,346 Pfizer shares in Q1 2023, an estimated $5.04M.
  • Van Leeuwen & Company first reported a position in Pfizer in Q3 2018 and held it in 7 quarters.
  • Van Leeuwen & Company's Pfizer position peaked at $5.04M in Q4 2022.
  • 3,103 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Van Leeuwen & Company's 13F filing for Q1 2023, filed 8 May 2023.